

IN THE CLAIMS

Please amend claims 266-277. This listing of claims will replace all prior versions, and listings, of claims in the application.

1-251. (Canceled)

252. (Previously Presented): A substantially purified scFv antibody comprising the amino acid sequence encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442.

253-264. (Canceled)

265. (Previously Presented): An antibody or antigen binding portion thereof which immunospecifically binds to SEQ ID NO:3, wherein the antibody or antigen binding portion thereof comprises:

a) a variable heavy (VH) complementary determining region (CDR) 1 comprising the amino acid sequence of SEQ ID NO:61 or an amino acid sequence of a VH CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442;

b) a VH CDR2 comprising the amino acid sequence of SEQ ID NO:62 or an amino acid sequence of a VH CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442;

c) a VH CDR3 comprising the amino acid sequence of SEQ ID NO:63 or an amino acid sequence of a VH CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442;

d) a variable light (VL) CDR1 comprising the amino acid sequence of SEQ ID NO:64 or an amino acid sequence of a VL CDR1 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442;

e) a VL CDR2 comprising the amino acid sequence of SEQ ID NO:65 or an amino acid sequence of a VL CDR2 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442; and

f) a VL CDR3 comprising the amino acid sequence of SEQ ID NO:66 or an amino acid sequence of a VL CDR3 encoded by the cDNA insert of the plasmid deposited with the ATCC® as patent deposit number PTA-2442.

266. (Currently Amended): The antibody or antigen binding portion thereof of claim 265, wherein the antibody is a monoclonal antibody.

267. (Currently Amended): The antibody or antigen binding portion thereof of claim 265, wherein the antibody is a human antibody.

268. (Currently Amended): The antibody or antigen binding portion thereof of claim 265, wherein the antibody is a humanized antibody.

269. (Currently Amended): The antibody or antigen binding portion thereof of claim 265, wherein the antibody is a Fab fragment.

270. (Currently Amended): The antibody or antigen binding portion thereof of claim 265, wherein the antibody is a F(ab')₂ fragment.

271. (Currently Amended): The antibody or antigen binding portion thereof of claim 265, wherein the antibody is an scFv.

272. (Currently Amended): A conjugated The antibody or antigen binding portion thereof of

claim 265, wherein the antibody is conjugated to a therapeutic or drug moiety.

273. (Currently Amended): The conjugated antibody or antigen binding portion thereof of claim 272, wherein the therapeutic or drug moiety is selected from the group consisting of a cytotoxin, a therapeutic agent or a radioactive metal ion.

274. (Currently Amended): A conjugated ~~The~~ antibody or antigen binding portion thereof of claim 265, wherein the antibody is conjugated to a detectable substance.

275. (Currently Amended): The conjugated antibody or antigen binding portion thereof of claim 274, wherein the detectable substance is selected from the group consisting of an enzyme, a prosthetic group, a fluorescent material, a luminescent material, a bioluminescent material, and a radioactive material.

276. (Currently Amended): A kit comprising the ~~[[an]]~~ antibody or antigen binding portion thereof ~~or fragment thereof as in any one~~ of claim~~[[s]]~~ 265 or 274 and instructions for use.

277. (Currently Amended): A pharmaceutical composition comprising an antibody or antigen binding portion thereof according to any one of claims 265 or 272 and a pharmaceutically acceptable carrier.